- Home
- NVO
NVO
Novo Nordisk A/S
as 04-18-2025 1:40pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 530.0B | IPO Year: | N/A |
| Target Price: | $128.00 | AVG Volume (30 days): | 9.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.14 | EPS Growth: | 21.54 |
| 52 Week Low/High: | $57.28 - $148.15 | Next Earning Date: | 05-07-2025 |
| Revenue: | $40,314,376,667 | Revenue Growth: | 25.03% |
| Revenue Growth (this year): | 22.57% | Revenue Growth (next year): | 17.01% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Barrons.com
20 hours ago
Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows
Barrons.com
a day ago
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
TipRanks
a day ago
Eli Lilly jumps as results from weight-loss pill study rival competitor’s
Yahoo Finance Video
2 days ago
How Eli Lilly's GLP-1 pill could transform the weight-loss space
Investor's Business Daily
2 days ago
Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill
Investing.com
2 days ago
Novo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug race
Investopedia
2 days ago
Novo Nordisk Stock Drops on Eli Lilly Oral Weight-Loss Drug Success, Downgrade
Motley Fool
2 days ago
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.